-
In category NewsEvaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age
A randomized, placebo-controlled phase 2–3 trial examined the safety, immunogenicity, and efficacy of two doses of the BNT162b2 vaccine administered 21 days apart in 5-to-11-year-old children. 2,268 children were randomly assigned to receive two injections, 21 days apart, of either the BNT162b2 vaccine (at a dose level of 10 μg, selected during phase 1) or […]
-
In category NewsEffectiveness of the quadrivalent high-dose influenza vaccine for prevention of cardiovascular and respiratory events in people aged 65 years and above
Influenza has been an acknowledged cause of respiratory disease for decades. However, considerable related, and often unappreciated, disease burden stems from cardiovascular complications, exacerbations of underlying medical conditions and secondary respiratory complications, with the highest burden in the elderly. This study combines the gold standard method of a randomized controlled trial with real-world data collection […]
-
In category NewsVaccine-preventable disease incidence of pneumococcal conjugate vaccine in the Finnish invasive pneumococcal disease vaccine trial
Streptococcus pneumoniae, pneumococcus, causes a number of different clinical syndromes including invasive diseases like meningitis and sepsis/bacteraemia, pneumonia and upper respiratory infections like otitis media in children and sinusitis in adults. The disease burden is highest among infants and the elderly. Pneumococcus remains the number one killer in developing countries, especially due to the high disease burden of pneumonia, but mortality […]